Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) and OSR (NASDAQ:OSRH – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.
Valuation & Earnings
This table compares Anavex Life Sciences and OSR”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anavex Life Sciences | N/A | N/A | -$46.38 million | ($0.39) | -8.23 |
| OSR | $2.91 million | 7.12 | -$27.06 million | ($0.37) | -1.59 |
Profitability
This table compares Anavex Life Sciences and OSR’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anavex Life Sciences | N/A | -32.73% | -30.15% |
| OSR | -593.15% | -8.28% | -6.18% |
Institutional and Insider Ownership
31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by company insiders. Comparatively, 36.9% of OSR shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Anavex Life Sciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, OSR has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Anavex Life Sciences and OSR, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anavex Life Sciences | 1 | 1 | 3 | 0 | 2.40 |
| OSR | 1 | 0 | 0 | 0 | 1.00 |
Anavex Life Sciences presently has a consensus price target of $21.33, indicating a potential upside of 564.59%. Given Anavex Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than OSR.
Summary
OSR beats Anavex Life Sciences on 8 of the 13 factors compared between the two stocks.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
About OSR
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
